• The remaining efficacy of omicron boosters: 5 studies

    As researchers study how well the omicron-targeting boosters work against the now-dominant subvariant XBB.1.5, here's what five recent studies found:
  • FDA approves expanded use of cancer drug Tecentriq

    The FDA recently approved an immunotherapy drug called Tecentriq (atezolizumab) for patients ages 2 and up who have advanced alveolar soft part sarcoma that has spread to other parts of the body or cannot be removed by surgery, U.S. News & World Report reported Jan. 2.
  • 96 drugs lost exclusivity in 2022

    In 2022, the FDA approved 96 first-time generic drugs. 
  • Baptist Health selects new pharmacy director

    Baptist Health Floyd named Evan Hampton, PharmD, its pharmacy director, effective Jan. 1. 
  • Federal investigation blames FDA, Biogen for Aduhelm scandal

    Murky documentation of meetings between Biogen and the FDA, plus an "unjustifiably high price" for a drug that lacked clinical data, are at fault for the Adulelm controversy, two House committees said Dec. 29 in a report. 
  • Pfizer scores win in hemophilia B gene therapy study

    Pfizer's hemophilia B gene therapy that's designed for the patient to produce factor IX, a blood-clotting protein, was effective and safe in a phase 3 study, the drugmaker said Dec. 29. 
  • Hospital pharmacy director appointed to Florida pharmacy board

    Maja Gift, Tampa General Hospital's pharmacy services administrator, was reappointed to Florida's board of pharmacy Dec. 28 alongside six other appointments. 
  • 5 health systems win pharmacy services awards

    The American Society of Health-System Pharmacists bestowed five health systems with "best practices" awards in early December. 
  • The COVID-19 treatment landscape

    After virus mutations spurred the FDA to yank Eli Lilly's COVID-19 drug from the market, public health experts told Becker's their predictions for the future of COVID-19 treatments. 
  • 10 systems seeking pharmacy leaders

    The following 10 hospitals, health systems and hospital operators have posted job listings seeking pharmacy leaders in the last week.
  • Walgreens pharmacist lists solutions to pediatric pain med shortage

    As this season's flu and respiratory syncytial virus season rattles healthcare's resources, and as retail pharmacies ration common pediatric drugs because of high demand, Walgreens pharmacy manager Amy Moser, PharmD, recommends parents be mindful of which medications they need for their children. 
  • Pfizer's meningococcal vaccine candidate clears regulatory step

    The FDA accepted Pfizer's biologics license application for its pentavalent meningococcal vaccine candidate intended for people between the ages of 10 and 25. 
  • 6 nitrosamine drug recalls in 2022

    Since 2019, the FDA has reported dozens of drug recalls because of the presence of nitrosamine, a probable carcinogen that largely pulls blood pressure treatments off the market. 
  • FDA tentatively approves multiple sclerosis drug

    India-based drugmaker Aurobindo Pharma received a tentative approval from the FDA for its dimethyl fumarate capsules to treat multiple sclerosis, CNBC reported Dec. 27. 
  • 50 drugs on Mark Cuban's pharmacy with biggest cost reductions

    Nearly a year after launching the online pharmacy Mark Cuban Cost Plus Drug Co., the company has hundreds of generics, more than 1 million customers, and partnerships with pharmacy benefit managers and payers. 
  • Congress passes bill with multiple drug supply provisions: 4 notes

    Congress passed an end-of-year bill Dec. 23 that includes withdrawing a federal barrier to pharmacists prescribing an opioid overdose treatment and numerous strategies to manage persistent drug supply problems. 
  • Will Plan B One-Step pill cause an abortion? FDA says 'no'

    The so-called morning after pill, Plan B One-Step (and generic versions of the drug, levonorgestrel), does not cause abortions, the FDA confirmed Dec. 23, despite packaging information that suggests otherwise.
  • New HIV drug approved by FDA for adults with few treatment options 

    Sunlenca, a new HIV drug for patients with limited available treatment options, was approved Dec. 22 by the FDA. The new drug is an option for adults with HIV who cannot tolerate, are resistant to or have safety issues with other established treatments for the disease.
  • 'This won't be over in a week or 2': Wisconsin hospitals, pharmacies ration Tamiflu

    Wisconsin hospitals and pharmacies are limiting their Tamiflu prescriptions in the face of severe shortages, NBC affiliate WMTV reported Dec. 20.
  • 3rd death tied to Alzheimer's experimental drug trial

    A third death has been tied to experimental Alzheimer's drug lecanemab, amplifying concerns about its safety, Science reported Dec. 21.

Featured Whitepapers

Featured Webinars